MPR

Anticoagulant Reversal Agent Andexxa Removed From the Market

Andexxa is a recombinant modified human factor Xa protein that received accelerated approval in 2018 for reversal of anticoagulation with rivaroxaban or apixaban due to life-threatening or ...
MPR

FDA Approves Fesilty for Congenital Fibrinogen Deficiency

Fesilty is supplied as a lyophilized powder for reconstitution in a single-dose vial containing approximately 1g of human fibrinogen.
MPR

Efficacy and Safety of Bisphosphonates Explored in Complex Regional Pain Syndrome

Bisphosphonates may reduce pain intensity in short term, but may result in little to no difference in immediate and medium term.
MPR

Proportion of Newborns Not Receiving Vitamin K Up From 2017 to 2024

HealthDay News — The proportion of newborns not receiving intramuscular vitamin K increased from 2017 to 2024, according to a research letter published online December 8 in the Journal of the American ...
MPR

FDA Adds Brain Tumor Warning to Depo-Provera Birth Control Shot

HealthDay News — The US Food and Drug Administration (FDA) approved a new safety warning for Depo-Provera, a widely used birth control shot made by Pfizer, alerting patients to a possible risk for a ...
MPR

HHS Moves to Halt Pediatric Gender-Affirming Interventions

The proposed regulatory action would bar hospitals from providing pediatric patients (those under the age of 18 years) from receiving gender-affirming procedures, including pharmaceutical and surgical ...
MPR

Voyxact (sibeprenlimab-szsi) to Reduce Proteinuria in Adults With Primary IgA Nephropathy at Risk for Progression

Dr Dana Rizk is Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB) and a VOYXACT VISIONARY Study Investigator and Co-Chair of the Steering Committee.
MPR

Zasocitinib Meets Coprimary Endpoints in Phase 3 Psoriasis Trials

The coprimary endpoints were the proportion of zasocitinib-treated patients achieving static Physician Global Assessment (sPGA) of clear (0) or almost clear (1) and Psoriasis Area and Severity Index ...
MPR

Oral Orforglipron Maintains Weight Loss After Switch From Injectable Therapies

According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.
MPR

Rybrevant Faspro Receives FDA Approval for All Amivantamab Indications

The Food and Drug Administration (FDA) has approved Rybrevant Faspro™, a subcutaneous (SC) formulation of amivantamab for all indications approved for the ...
MPR

TRITON3 Data Lead to Full FDA Approval of Rubraca in mCRPC

TRITON3 trial data support FDA traditional approval of rucaparib for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer.
MPR

Flu Season Starts Early in NYC as Cases Rise Fast

HealthDay News — Flu season is getting an early start in New York City, with doctors reporting a sharp jump in cases weeks sooner than normal.